{"id":36127,"date":"2026-09-11T17:39:00","date_gmt":"2026-09-11T12:09:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36127"},"modified":"2026-09-11T12:50:18","modified_gmt":"2026-09-11T07:20:18","slug":"adbry-vs-dupixent-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis","title":{"rendered":"ADBRY vs DUPIXENT: The Battle for Atopic Dermatitis Supremacy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6aa40ae53d3d8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6aa40ae53d3d8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Atopic_Dermatitis_Prevalence_Burden_and_Market_Size\" >Atopic Dermatitis: Prevalence, Burden, and Market Size<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#DUPIXENT_The_First-Mover_Biologic\" >DUPIXENT: The First-Mover Biologic<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#DUPIXENT_Alternatives_and_DUPIXENT_Competitors\" >DUPIXENT Alternatives and DUPIXENT Competitors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#How_is_DUPIXENT_Performing_in_the_Atopic_Dermatitis_Market\" >How is DUPIXENT Performing in the Atopic Dermatitis Market?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#ADBRY_The_Targeted_IL-13_Challenger\" >ADBRY: The Targeted IL-13 Challenger<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#ADBRYs_Commercial_Momentum\" >ADBRY&#8217;s Commercial Momentum<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Atopic_Dermatitis_Drug_Pipeline_Emerging_Competitors_for_DUPIXENT_and_ADBRY\" >Atopic Dermatitis Drug Pipeline: Emerging Competitors for DUPIXENT and ADBRY<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#LEO_Pharmas_Temtokibart\" >LEO Pharma\u2019s Temtokibart<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Connect_Biopharmas_Rademikibart_CBP-201\" >Connect Biopharma\u2019s Rademikibart (CBP-201)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#UNION_Therapeutics_Orismilast\" >UNION Therapeutics\u2019 Orismilast<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Biosion_and_Aclaris_Therapeutics_Bosakitug_BSI-045B\" >Biosion and Aclaris Therapeutics\u2019 Bosakitug (BSI-045B)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#RocheGenentechs_Afimkibart_RG6631\" >Roche\/Genentech\u2019s Afimkibart (RG6631)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Nektar_Therapeutics_Rezpegaldesleukin\" >Nektar Therapeutics\u2019 Rezpegaldesleukin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Apogee_Therapeutics_APG777\" >Apogee Therapeutics\u2019 APG777<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#ADBRY_vs_DUPIXENT_and_Beyond_The_Future_of_Atopic_Dermatitis_Treatment\" >ADBRY vs DUPIXENT and Beyond: The Future of Atopic Dermatitis Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>For decades, moderate-to-severe atopic dermatitis (AD) was managed with topical steroids, calcineurin inhibitors, and broad immunosuppressants, until targeted biologics transformed care.<\/em><\/li>\n\n\n\n<li><em>Two biologics dominate: DUPIXENT (dupilumab) by Sanofi\/Regeneron and ADBRY (tralokinumab) by LEO Pharma; both target the Type 2 (Th2) immune pathway but differ in mechanism, approval timing, and market position.<\/em><\/li>\n\n\n\n<li><em>Several promising competitors, such as LEO Pharma\u2019s Temtokibart, Connect Biopharma\u2019s Rademikibart (CBP-201), UNION Therapeutics\u2019 Orismilast, Biosion and Aclaris Therapeutics\u2019 Bosakitug (BSI-045B), Roche\/Genentech\u2019s Afimkibart (RG6631), Nektar Therapeutics\u2019 Rezpegaldesleukin, and Apogee Therapeutics\u2019 APG777, are under development that will give tough competition to DUPIXENT and ADBRY.<\/em><\/li>\n<\/ul>\n\n\n\n<p>For decades, moderate-to-severe atopic dermatitis left patients cycling through topical steroids, calcineurin inhibitors, and, in the worst cases, broad immunosuppressants that came with a long list of trade-offs. That changed with the arrival of targeted biologics. Today, two names dominate the conversation in dermatology clinics and in every atopic dermatitis pipeline analysis: <strong>Sanofi\/Regeneron\u2019s DUPIXENT (dupilumab)<\/strong> and <strong>Leo Pharma\u2019s ADBRY (tralokinumab)<\/strong>. Both drugs interrupt the same inflammatory storyline, the Type 2 (Th2) immune pathway, but they do it differently; they were approved years apart, and they occupy very different positions in the atopic dermatitis treatment market today.<\/p>\n\n\n\n<p>This ADBRY vs DUPIXENT comparison breaks down how each biologic works, how they&#8217;re priced, how they&#8217;re performing commercially in 2025 and 2026, and, perhaps most importantly for anyone tracking the atopic dermatitis drug pipeline, which emerging therapeutic assets could reshape this competitive landscape in the years ahead.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-atopic-dermatitis-prevalence-burden-and-market-size\"><span class=\"ez-toc-section\" id=\"Atopic_Dermatitis_Prevalence_Burden_and_Market_Size\"><\/span><strong>Atopic Dermatitis: Prevalence, Burden, and Market Size<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Atopic dermatitis prevalence is far higher than most people assume. Globally, AD affects an estimated <strong>200 million-plus people<\/strong>, and in the U.S. alone, roughly <strong>16.5 million<\/strong> adults live with the condition, alongside millions of children. A meaningful share of this population, often cited at around <strong>30-40%<\/strong>, has moderate-to-severe disease that topical therapy alone cannot control. That&#8217;s the population driving the moderate-to-severe atopic dermatitis market and the systemic, biologic-eligible segment that DUPIXENT and ADBRY were built to serve.<\/p>\n\n\n\n<p>Based on DelveInsight&#8217;s assessment in 2025, the 7MM had approximately <strong>53 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-ad-epidemiology-forecast\">diagnosed prevalent cases of atopic dermatitis<\/a>. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period. Among the 7MM, the US accounted for the highest prevalent cases (<strong>~45%<\/strong>) of moderate-to-severe atopic dermatitis in 2025.<\/p>\n\n\n\n<p>The disease burden goes well beyond visible rashes. Chronic itch, disrupted sleep, secondary skin infections, and the psychological toll of a visible, relapsing-remitting condition combine to make AD one of the highest-burden chronic dermatologic diseases in terms of quality-of-life impact. That burden, plus a long stretch of unmet need before biologics arrived, is exactly why the atopic dermatitis market size has expanded so dramatically over the past decade.<\/p>\n\n\n\n<p>The atopic dermatitis market has been valued in the range of roughly <strong>$13 billion<\/strong> across the 7MM in 2025, projecting the atopic dermatitis drugs market to climb toward <strong>$28 billion<\/strong> by 2036 at a compound annual growth rate of roughly <strong>7%<\/strong>. The moderate-to-severe atopic dermatitis market, the segment where ADBRY and DUPIXENT compete head-on, is the single biggest growth engine in this space, as biologics increasingly displace older systemic immunosuppressants like cyclosporine and methotrexate.<\/p>\n\n\n\n<p>This growth isn&#8217;t just about more patients being diagnosed; it&#8217;s about deeper biologic penetration, expanding pediatric approvals, and a fast-maturing atopic dermatitis drug pipeline of next-generation agents entering the market. For any company specializing in atopic dermatitis market analysis, this combination of high unmet need, strong pricing power, and multiple approved mechanisms makes AD one of dermatology&#8217;s most closely watched therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dupixent-the-first-mover-biologic\"><span class=\"ez-toc-section\" id=\"DUPIXENT_The_First-Mover_Biologic\"><\/span><strong>DUPIXENT: The First-Mover Biologic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sanofi and Regeneron&#8217;s DUPIXENT (dupilumab) didn&#8217;t just enter the <a href=\"https:\/\/www.delveinsight.com\/blog\/dupixent-market\">atopic dermatitis medication market<\/a>; it created the modern biologic category for AD. Approved by the FDA in March 2017, DUPIXENT became the first targeted biologic indicated for moderate-to-severe atopic dermatitis, and it has spent the years since building one of the deepest label footprints in all of dermatology and immunology. The DUPIXENT timeline since then has been aggressive.&nbsp;<\/p>\n\n\n\n<p>DUPIXENT is a fully human monoclonal antibody that binds to the <strong>IL-4 receptor alpha (IL-4R\u03b1)<\/strong> subunit, a shared component of both the IL-4 and IL-13 receptor complexes. By blocking IL-4R\u03b1, dupilumab inhibits signaling from both IL-4 and IL-13 simultaneously, the two central cytokines driving Type 2 inflammation in atopic dermatitis, asthma, and several other allergic conditions. This dual-cytokine blockade is a key reason DUPIXENT has been able to expand into so many additional indications beyond AD.<\/p>\n\n\n\n<p>Beyond AD, DUPIXENT now also carries FDA approvals in asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, <a href=\"https:\/\/www.delveinsight.com\/blog\/dupixent-for-copd\">COPD treatment<\/a>, and, as of June 2025, bullous pemphigoid, its eighth U.S. indication. This &#8220;pipeline-in-a-product&#8221; strategy is central to how Sanofi has scaled the brand.<\/p>\n\n\n\n<p>DUPIXENT&#8217;s U.S. wholesale acquisition cost (WAC) has risen since launch. It debuted at roughly <strong>$37,000 <\/strong>per year in 2017; the current list price sits at approximately <strong>$4,193<\/strong> per four-week carton, translating to an annual WAC north of <strong>$50,000<\/strong> before rebates, discounts, and copay assistance. Most commercially insured patients, thanks to manufacturer copay programs, pay a small fraction of that list price out of pocket. In Europe, list prices are typically negotiated 20-30% lower than U.S. WAC.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dupixent-alternatives-and-dupixent-competitors\"><span class=\"ez-toc-section\" id=\"DUPIXENT_Alternatives_and_DUPIXENT_Competitors\"><\/span><strong>DUPIXENT Alternatives and DUPIXENT Competitors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Despite its first-mover advantage, DUPIXENT has never had the atopic dermatitis treatment market entirely to itself, and the landscape of DUPIXENT alternatives has continued to expand. Among the key direct competitors in the biologic segment is <strong>ADBRY (tralokinumab)<\/strong>, developed by <strong>LEO Pharma<\/strong> as a selective IL-13 inhibitor. Another notable emerging competitor is <strong>EBGLYSS (lebrikizumab)<\/strong>, developed by <strong>Eli Lilly and Almirall<\/strong>, which specifically targets IL-13 and has gained attention for its less-frequent maintenance dosing.&nbsp;<\/p>\n\n\n\n<p><em>Sadaf Javed, Functional Head of Forecasting &amp; Analytics at DelveInsight, stated that we view EBGLYSS as a significant competitive threat to DUPIXENT, with some forecasts projecting sales approaching USD 3.3 billion by 2036.&nbsp;<\/em><\/p>\n\n\n\n<p>The competitive landscape also includes oral JAK inhibitors such as <strong>RINVOQ (upadacitinib) and CIBINQO (abrocitinib)<\/strong>, which provide a needle-free treatment option for patients who prefer oral therapies over injectable biologics. However, these therapies carry boxed-warning safety considerations that distinguish them from biologic treatments. In addition, topical therapies such as <strong>EUCRISA, OPZELURA, and <\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/zoryve-for-atopic-dermatitis-treatment\"><strong>ZORYVE<\/strong><\/a><strong> <\/strong>continue to serve as important non-systemic alternatives, particularly for patients with milder disease or as adjunctive treatments alongside systemic therapies.&nbsp;<\/p>\n\n\n\n<p>This growing roster of DUPIXENT alternatives means dermatologists increasingly have room to individualize treatment based on dosing frequency, administration route (injection vs. oral), safety profile, and payer coverage, a shift that is gradually chipping away at DUPIXENT&#8217;s historical share of new-patient starts even as its overall revenue continues to climb.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-how-is-dupixent-performing-in-the-atopic-dermatitis-market\"><span class=\"ez-toc-section\" id=\"How_is_DUPIXENT_Performing_in_the_Atopic_Dermatitis_Market\"><\/span><strong>How is DUPIXENT Performing in the Atopic Dermatitis Market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>By any measure, DUPIXENT atopic dermatitis market performance remains extraordinary. In full-year 2025, Sanofi reported total DUPIXENT sales of <strong>\u20ac15.7 billion<\/strong>, a <strong>25.2%<\/strong> increase over the prior year, with global quarterly sales exceeding <strong>\u20ac4 billion<\/strong> for two consecutive quarters in the second half of the year. That growth was driven by volume gains across the full spread of approved indications: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, COPD, and bullous pemphigoid. Atopic dermatitis itself remains the single largest contributor to that figure, with dermatology-specific revenue estimated at closing in on <strong>$10-11 billion<\/strong> for the year across major markets.<\/p>\n\n\n\n<p>Looking ahead, <a href=\"https:\/\/www.delveinsight.com\/report-store\/dupixent-market-size-forecast-and-market-insight\">DUPIXENT market forecasts<\/a> remain bullish. Sanofi has previously guided toward DUPIXENT sales approaching <strong>\u20ac20-22 billion<\/strong> by the end of the decade, supported by continued volume growth in low-penetration markets, newly launched indications like COPD and CSU still ramping, and pediatric expansion. The company&#8217;s how-long-has-DUPIXENT-been-on-the-market story, nearly a decade of continuous label growth since 2017, has effectively turned dupilumab into a platform drug rather than a single-indication product, and that diversification is exactly what continues to insulate its atopic dermatitis market performance from single-indication competitive pressure. That said, as IL-13-selective and orally administered rivals mature, DUPIXENT&#8217;s share of new AD patient starts is expected to erode gradually even as total revenue keeps climbing on the back of its broader label.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"351\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-1024x351.webp\" alt=\"DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM,-in-USD-Million\" class=\"wp-image-36134\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-1024x351.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-300x103.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-150x51.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-768x263.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million-1536x526.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/DUPIXENT-and-ADBRY-Market-Size-of-Atopic-Dermatitis-in-7MM-in-USD-Million.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adbry-the-targeted-il-13-challenger\"><span class=\"ez-toc-section\" id=\"ADBRY_The_Targeted_IL-13_Challenger\"><\/span><strong>ADBRY: The Targeted IL-13 Challenger<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>If DUPIXENT proved biologics could work in atopic dermatitis, <strong>LEO Pharma&#8217;s ADBRY (tralokinumab)<\/strong> was designed to prove that a more selective mechanism could work just as well, or better, for the right patients. Marketed as ADTRALZA outside the U.S., tralokinumab became the first FDA-approved biologic to specifically and exclusively target IL-13, positioning it as a more surgical alternative among approved drugs for atopic dermatitis.<\/p>\n\n\n\n<p>Unlike DUPIXENT&#8217;s dual IL-4\/IL-13 blockade, ADBRY is a high-affinity human IgG4 monoclonal antibody that binds specifically to the IL-13 cytokine itself, not the receptor, neutralizing its interaction with both the IL-13R\u03b11\/IL-4R\u03b1 receptor complex and the IL-13R\u03b12 &#8220;decoy&#8221; receptor. Because IL-13, rather than IL-4, is now understood to be the dominant driver of skin-specific inflammation in atopic dermatitis, this targeted approach lets ADBRY deliver meaningful efficacy while leaving the IL-4 pathway, more central to systemic allergic responses, largely untouched.<\/p>\n\n\n\n<p>In the United States, ADBRY was first approved in December 2021 for adults, with the indication later expanded to adolescents aged 12\u201317 years and, more recently, complemented by the introduction of a convenient single-dose autoinjector. In the EU4 and broader European Union markets, the European Commission approved in June 2021 for adults, followed by an extension to adolescents in 2022, placing ADBRY\/ADTRALZA\u2019s European approval timeline slightly ahead of its U.S. approval. In the United Kingdom, ADTRALZA received approval from the MHRA for adults and was subsequently approved for use in adolescents aged 12\u201317 years. In Japan, the Ministry of Health, Labour and Welfare (MHLW) approved the therapy in December 2022 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\">adults with atopic dermatitis<\/a> inadequately controlled by conventional therapies.<\/p>\n\n\n\n<p>ADTRALZA\/ADBRY is now available in roughly 20 markets worldwide, including Canada, Switzerland, the UAE, Saudi Arabia, and South Korea, reflecting a steady international rollout since its first EU nod. ADBRY launched at a wholesale acquisition cost modestly below DUPIXENT&#8217;s, roughly <strong>$3,349 <\/strong>for a one-month supply at its initial 300 mg every-other-week maintenance dosing, versus DUPIXENT&#8217;s list price in the <strong>$4,000+<\/strong> per-month range. That relative pricing positioning has been part of LEO Pharma&#8217;s competitive strategy: offering payers and patients a clinically comparable, more narrowly targeted biologic at a somewhat more favorable list price.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-adbry-s-commercial-momentum\"><span class=\"ez-toc-section\" id=\"ADBRYs_Commercial_Momentum\"><\/span><strong>ADBRY&#8217;s Commercial Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>ADBRY&#8217;s trajectory illustrates how a well-differentiated challenger can carve out real share even against an entrenched first-mover. LEO Pharma, which is privately held and reports in Danish kroner (DKK), closed 2025 with total company revenue up 10% at constant exchange rates to <strong>DKK 13,499 million<\/strong>, and dermatology revenue, led by the &#8220;Strategic brands&#8221; ADTRALZA\/ADBRY, ANZUPGO, AND SPEVIGO, grew even faster, with those combined strategic brands posting a 48% revenue increase at constant exchange rates. Tralokinumab has been LEO Pharma&#8217;s largest product since at least 2024, and North America, its most important growth engine, expanded 35% at constant exchange rates in 2025 alone<\/p>\n\n\n\n<p>That North America-led acceleration matters enormously for ADBRY&#8217;s commercial story, because the U.S. is both the highest-value AD market and the one where DUPIXENT&#8217;s incumbency has historically been hardest to dislodge. ADBRY&#8217;s continued double-digit-to-triple-digit percentage growth in recent years, even as it remains a smaller absolute revenue base than DUPIXENT, signals genuine physician and payer acceptance of a second, differentiated IL-13-targeted option. Looking forward, LEO Pharma has guided to continued double-digit revenue growth for 2026, with ADBRY\/ADTRALZA named as a primary driver alongside newer launches. As additional indications, pediatric extensions, and potential combination strategies mature, ADBRY&#8217;s future promise lies in becoming a durable, profitable #2 in the biologics segment of the atopic dermatitis treatment market, even if it may never fully match DUPIXENT&#8217;s broader multi-indication scale.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-atopic-dermatitis-drug-pipeline-emerging-competitors-for-dupixent-and-adbry\"><span class=\"ez-toc-section\" id=\"Atopic_Dermatitis_Drug_Pipeline_Emerging_Competitors_for_DUPIXENT_and_ADBRY\"><\/span><strong>Atopic Dermatitis Drug Pipeline: Emerging Competitors for DUPIXENT and ADBRY<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/atopic-dermatitis-treatment-pipeline\">atopic dermatitis pipeline<\/a> 2026 story is arguably as important as the DUPIXENT-vs-ADBRY rivalry itself. A wave of emerging therapies, spanning new mechanisms, better dosing intervals, and next-generation IL-13 biology, is advancing through mid-to-late-stage trials, and several are positioned to directly challenge both incumbents once approved.&nbsp;<\/p>\n\n\n\n<p><em>Here&#8217;s where the leading therapeutic assets for atopic dermatitis phase overview currently stand<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-leo-pharma-s-temtokibart\"><span class=\"ez-toc-section\" id=\"LEO_Pharmas_Temtokibart\"><\/span><strong>LEO Pharma\u2019s Temtokibart<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>This <strong>IL-22RA1-targeting monoclonal antibody<\/strong> takes a genuinely novel mechanistic approach, targeting the IL-22 receptor rather than the IL-4\/IL-13 axis. Phase 2b data showed the top three doses beating placebo on EASI improvement at 16 weeks, and biomarker data presented at EADV 2025 showed a 97% improvement in immune gene expression along with restoration of epidermal barrier-related genes, pointing to a possible barrier-repair advantage layered on top of anti-inflammatory activity. Notably, this is LEO Pharma&#8217;s own next-generation candidate, meaning the company could eventually offer a multi-mechanism AD portfolio alongside ADBRY.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-connect-biopharma-s-rademikibart-cbp-201\"><span class=\"ez-toc-section\" id=\"Connect_Biopharmas_Rademikibart_CBP-201\"><\/span><strong>Connect Biopharma\u2019s Rademikibart (CBP-201)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>An <strong>IL-4R\u03b1-targeting antibody<\/strong> mechanistically similar to dupilumab, rademikibart delivered strong Phase 3 data from its China-based RADIANT-AD trial, presented as a late-breaking oral presentation at the 2026 AAD Annual Meeting. The study showed roughly 87% of patients achieving IGA 0\/1 response and about 85% reaching EASI-90 at 52 weeks, with safety comparable to placebo and lower reported conjunctivitis than other agents in its class, a differentiator dermatologists watch closely given conjunctivitis rates associated with existing IL-4R\u03b1\/IL-13 biologics.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"377\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-1024x377.webp\" alt=\"Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development\" class=\"wp-image-36133\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-1024x377.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-300x110.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-150x55.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-768x282.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development-1536x565.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Comparison-of-Emerging-Atopic-Dermatitis-Therapies-Under-Development.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-union-therapeutics-orismilast\"><span class=\"ez-toc-section\" id=\"UNION_Therapeutics_Orismilast\"><\/span><strong>UNION Therapeutics\u2019 Orismilast<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A next-generation <strong>oral <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pde4b-inhibitors-market-forecast\"><strong>PDE4B\/D inhibitor<\/strong><\/a>, orismilast offers a needle-free option distinct from the injectable biologics dominating this space. Its <strong>Phase 2b ADESOS trial<\/strong> met its primary endpoint, with all three dose arms achieving statistically significant IGA 0\/1 responses versus placebo and fast, statistically significant itch reduction as early as week 2. Having received FDA Fast Track designation, UNION is now advancing plans for Phase 3 development, positioning orismilast as a potential oral alternative for patients who want to avoid injections altogether.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-biosion-and-aclaris-therapeutics-bosakitug-bsi-045b\"><span class=\"ez-toc-section\" id=\"Biosion_and_Aclaris_Therapeutics_Bosakitug_BSI-045B\"><\/span><strong>Biosion and Aclaris Therapeutics\u2019 Bosakitug (BSI-045B)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>An <strong>anti-TSLP monoclonal antibody<\/strong>, bosakitug targets thymic stromal lymphopoietin, an &#8220;alarmin&#8221; cytokine positioned further upstream in the inflammatory cascade than IL-4 or IL-13. Strong single-arm Phase 2a results showed EASI-75 in 94% of participants and IGA 0\/1 responses in 88%. A randomized, placebo-controlled Phase 2 trial has since completed enrollment, with top-line data expected in Q4 2026, a readout that will be closely watched given bosakitug&#8217;s potential best-in-class positioning and long, roughly 23-day half-life.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-roche-genentech-s-afimkibart-rg6631\"><span class=\"ez-toc-section\" id=\"RocheGenentechs_Afimkibart_RG6631\"><\/span><strong>Roche\/Genentech\u2019s Afimkibart (RG6631)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Originally developed for inflammatory bowel disease, this <strong>anti-TL1A antibody<\/strong> is now being evaluated in a dedicated Phase 2 <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-to-severe-atopic-dermatitis-pipeline-insight\">trial for moderate-to-severe atopic dermatitis<\/a>, exploring a non-Type-2 inflammatory pathway that&#8217;s mechanistically distinct from every other major AD biologic on this list. It&#8217;s an earlier-stage bet than most of its peers here, with regulatory filings for AD not anticipated until 2027 at the earliest, but its novel mechanism makes it one to watch for patients who don&#8217;t respond well to Type 2-targeted therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-nektar-therapeutics-rezpegaldesleukin\"><span class=\"ez-toc-section\" id=\"Nektar_Therapeutics_Rezpegaldesleukin\"><\/span><strong>Nektar Therapeutics\u2019 Rezpegaldesleukin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>An IL-2 pathway agonist designed to selectively expand <strong>regulatory T-cells (Tregs)<\/strong>, rezpegaldesleukin takes an entirely different immunological approach, rebalancing the immune system rather than blocking a single inflammatory cytokine. Its <strong>Phase 2b REZOLVE-AD study<\/strong> met its primary and key secondary endpoints, and maintenance data presented in 2026 showed durable, deepening responses with both monthly and quarterly dosing, a potentially major convenience advantage. Nektar is now planning to launch its <strong>Phase 3 ZENITH-AD program<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-apogee-therapeutics-apg777\"><span class=\"ez-toc-section\" id=\"Apogee_Therapeutics_APG777\"><\/span><strong>Apogee Therapeutics\u2019 APG777<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A half-life-extended <strong>anti-IL-13 antibody<\/strong> engineered for infrequent dosing, APG777 (recently assigned the INN &#8220;zumilokibart&#8221;) posted a roughly 77-day half-life in Phase 1 data and has since shown 52-week Phase 2 APEX data demonstrating durable, deepening responses with dosing as infrequent as every 3 or 6 months. If confirmed in Phase 3, that dosing interval, compared to the every-2-week regimens of DUPIXENT and ADBRY, could be a genuine game-changer for patient convenience and adherence. Apogee is also testing APG777 in combination with an anti-OX40L antibody (as APG279) head-to-head against DUPIXENT, with a 2H 2026 readout expected, and is targeting a potential 2029 launch.<\/p>\n\n\n\n<p>Collectively, these atopic dermatitis pipeline drugs represent a much broader diversification of mechanism than the market has seen before, moving beyond the &#8220;block IL-4\/IL-13&#8221; playbook into TSLP, IL-22RA1, TL1A, and Treg-based approaches, alongside next-generation, longer-acting IL-13 and IL-4R\u03b1 antibodies. For companies specializing in atopic dermatitis market analysis, this pipeline breadth suggests the next five years will bring not just more competition for DUPIXENT and ADBRY, but genuinely new treatment paradigms for patients who don&#8217;t respond adequately to today&#8217;s biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-adbry-vs-dupixent-and-beyond-the-future-of-atopic-dermatitis-treatment\"><span class=\"ez-toc-section\" id=\"ADBRY_vs_DUPIXENT_and_Beyond_The_Future_of_Atopic_Dermatitis_Treatment\"><\/span><strong>ADBRY vs DUPIXENT and Beyond: The Future of Atopic Dermatitis Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>So, ADBRY vs DUPIXENT, which is &#8220;better&#8221;? The honest answer is that there&#8217;s no universal winner. DUPIXENT remains the most extensively studied, broadly labeled, and commercially dominant biologic in atopic dermatitis, backed by nearly a decade of real-world data and a label that now spans eight distinct indications. ADBRY offers a more targeted IL-13-only mechanism, a somewhat more favorable list price, and a commercial trajectory that shows a genuine, sustainable challenger can carve out meaningful share even against an entrenched leader.<\/p>\n\n\n\n<p>For patients and prescribers, the choice increasingly comes down to individual factors: prior treatment history, comorbid Type 2 conditions (where DUPIXENT&#8217;s broader label may matter), tolerance for injection frequency, insurance formulary placement, and side-effect profile. And for anyone tracking the <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\">atopic dermatitis treatment landscape<\/a> more broadly, the real story isn&#8217;t just ADBRY versus DUPIXENT; it&#8217;s the accelerating wave of pipeline agents, from oral PDE4 inhibitors to Treg-expanding biologics to half-life-extended antibodies dosed as infrequently as twice a year, that promise to make this one of the most dynamic corners of dermatology for years to come. As biologics gaining market share in atopic dermatitis in the US continue to diversify beyond these two original leaders, patients stand to benefit from more choice, better convenience, and, eventually, more competitive pricing across the board.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-1024x194.webp\" alt=\"Atopic Dermatitis Market Analysis\" class=\"wp-image-36132\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/Atopic-Dermatitis-Market-Analysis.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-frequently-asked-questions\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1789110822454\"><strong class=\"schema-faq-question\"><strong>How long has DUPIXENT been on the market?<\/strong><\/strong> <p class=\"schema-faq-answer\">DUPIXENT received its first FDA approval for atopic dermatitis in March 2017, making it nearly a decade old in the AD space as of 2026.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1789110880042\"><strong class=\"schema-faq-question\"><strong>Who is the DUPIXENT manufacturer?<\/strong><\/strong> <p class=\"schema-faq-answer\">DUPIXENT is jointly developed and marketed by Regeneron Pharmaceuticals and Sanofi.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1789110894919\"><strong class=\"schema-faq-question\"><strong>What are DUPIXENT&#8217;s approved indications?<\/strong><\/strong> <p class=\"schema-faq-answer\">DUPIXENT is approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1789110908775\"><strong class=\"schema-faq-question\"><strong>What are the main DUPIXENT alternatives?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key DUPIXENT competitors include ADBRY (tralokinumab), EBGLYSS (lebrikizumab), and oral JAK inhibitors such as RINVOQ (upadacitinib) and CIBINQO (abrocitinib).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1789110948951\"><strong class=\"schema-faq-question\"><strong>Who manufactures ADBRY?<\/strong><\/strong> <p class=\"schema-faq-answer\">ADBRY is manufactured by LEO Pharma, sold as ADTRALZA outside the United States.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1789110963474\"><strong class=\"schema-faq-question\"><strong>Are biologics gaining market share in the US atopic dermatitis market?<\/strong><\/strong> <p class=\"schema-faq-answer\">One of the clearest atopic dermatitis therapeutic advances of the last five years is the steady share shift from topical and conventional systemic therapies toward biologics. Biologics gaining market share in the U.S. atopic dermatitis space is now a defining trend: payer coverage has broadened, real-world safety data has accumulated, and dermatologists increasingly view biologics as first-line systemic therapy rather than a last resort. DUPIXENT and ADBRY sit at the center of that shift, alongside oral JAK inhibitors carving out a smaller but growing niche for patients who prefer pills over injections.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary For decades, moderate-to-severe atopic dermatitis left patients cycling through topical steroids, calcineurin inhibitors, and, in the worst cases, broad immunosuppressants that came with a long list of trade-offs. That changed with the arrival of targeted biologics. Today, two names dominate the conversation in dermatology clinics and in every atopic dermatitis pipeline analysis: Sanofi\/Regeneron\u2019s DUPIXENT [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18970,23105,7478,7466,7469,17926,4799],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-36127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-adbry","tag-adbry-vs-dupixent","tag-atopic-dermatitis","tag-atopic-dermatitis-pipeline","tag-atopic-dermatitis-treatment-market","tag-atopic-dermatitis-upcoming-therapies","tag-dupixent","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ADBRY vs DUPIXENT: The Atopic Dermatitis Treatment Showdown<\/title>\n<meta name=\"description\" content=\"Today, two names dominate the atopic dermatitis treatment landscape: Sanofi\/Regeneron\u2019s DUPIXENT and Leo Pharma\u2019s ADBRY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADBRY vs DUPIXENT: The Atopic Dermatitis Treatment Showdown\" \/>\n<meta property=\"og:description\" content=\"Today, two names dominate the atopic dermatitis treatment landscape: Sanofi\/Regeneron\u2019s DUPIXENT and Leo Pharma\u2019s ADBRY.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-11T12:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ADBRY vs DUPIXENT: The Atopic Dermatitis Treatment Showdown","description":"Today, two names dominate the atopic dermatitis treatment landscape: Sanofi\/Regeneron\u2019s DUPIXENT and Leo Pharma\u2019s ADBRY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis","og_locale":"en_US","og_type":"article","og_title":"ADBRY vs DUPIXENT: The Atopic Dermatitis Treatment Showdown","og_description":"Today, two names dominate the atopic dermatitis treatment landscape: Sanofi\/Regeneron\u2019s DUPIXENT and Leo Pharma\u2019s ADBRY.","og_url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-09-11T12:09:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"ADBRY vs DUPIXENT: The Battle for Atopic Dermatitis Supremacy","datePublished":"2026-09-11T12:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis"},"wordCount":3138,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp","keywords":["Adbry","ADBRY vs DUPIXENT","Atopic dermatitis","Atopic dermatitis pipeline","Atopic dermatitis Treatment Market","Atopic Dermatitis Upcoming Therapies","Dupixent"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis","url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis","name":"ADBRY vs DUPIXENT: The Atopic Dermatitis Treatment Showdown","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp","datePublished":"2026-09-11T12:09:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Today, two names dominate the atopic dermatitis treatment landscape: Sanofi\/Regeneron\u2019s DUPIXENT and Leo Pharma\u2019s ADBRY.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110822454"},{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110880042"},{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110894919"},{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110908775"},{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110948951"},{"@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110963474"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis.webp","width":466,"height":284,"caption":"adbry-vs-dupixent-in-atopic-dermatitis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110822454","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110822454","name":"How long has DUPIXENT been on the market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"DUPIXENT received its first FDA approval for atopic dermatitis in March 2017, making it nearly a decade old in the AD space as of 2026.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110880042","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110880042","name":"Who is the DUPIXENT manufacturer?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"DUPIXENT is jointly developed and marketed by Regeneron Pharmaceuticals and Sanofi.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110894919","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110894919","name":"What are DUPIXENT's approved indications?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"DUPIXENT is approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110908775","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110908775","name":"What are the main DUPIXENT alternatives?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key DUPIXENT competitors include ADBRY (tralokinumab), EBGLYSS (lebrikizumab), and oral JAK inhibitors such as RINVOQ (upadacitinib) and CIBINQO (abrocitinib).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110948951","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110948951","name":"Who manufactures ADBRY?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"ADBRY is manufactured by LEO Pharma, sold as ADTRALZA outside the United States.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110963474","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/adbry-vs-dupixent-in-atopic-dermatitis#faq-question-1789110963474","name":"Are biologics gaining market share in the US atopic dermatitis market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"One of the clearest atopic dermatitis therapeutic advances of the last five years is the steady share shift from topical and conventional systemic therapies toward biologics. Biologics gaining market share in the U.S. atopic dermatitis space is now a defining trend: payer coverage has broadened, real-world safety data has accumulated, and dermatologists increasingly view biologics as first-line systemic therapy rather than a last resort. DUPIXENT and ADBRY sit at the center of that shift, alongside oral JAK inhibitors carving out a smaller but growing niche for patients who prefer pills over injections.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/09\/adbry-vs-dupixent-in-atopic-dermatitis-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Adbry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ADBRY vs DUPIXENT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic dermatitis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dupixent<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adbry<\/span>","<span class=\"advgb-post-tax-term\">ADBRY vs DUPIXENT<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis pipeline<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Atopic Dermatitis Upcoming Therapies<\/span>","<span class=\"advgb-post-tax-term\">Dupixent<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 hours ago","modified":"Updated 1 hour ago"},"absolute_dates":{"created":"Posted on Sep 11, 2026","modified":"Updated on Sep 11, 2026"},"absolute_dates_time":{"created":"Posted on Sep 11, 2026 5:39 pm","modified":"Updated on Sep 11, 2026 12:50 pm"},"featured_img_caption":"adbry-vs-dupixent-in-atopic-dermatitis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36127"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36127\/revisions"}],"predecessor-version":[{"id":36135,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36127\/revisions\/36135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36130"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36127"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36127"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}